Retargeted Psychopharm

Aktuelle Version vom 18. Januar 2021, 20:19 Uhr

Psychopharm
32540682 2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.

Valproic acid
32498007 2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.

Chlorpromazine
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments

• paper

32593831 2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.
32425222 2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Clozapine
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.

Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic
32519753 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.
32380847 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence
32467020 2020. A...: Cannabidiol as a potential anti-inflammatory treatment? .
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
32576053 2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.

Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?